Breaking News

Merck KGaA, Maker of Erbitux Cancer Drug, to Acquire Sigma-Aldrich for $17 Billion
Tweet TWEET

RXi Pharmaceuticals to Present at 15th Annual BIO CEO & Investor Conference

  RXi Pharmaceuticals to Present at 15th Annual BIO CEO & Investor Conference

BIO CEO & Investor Conference 2013

Business Wire

WESTBOROUGH, Mass. -- February 4, 2013

RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused
on discovering, developing and commercializing innovative therapies addressing
major unmet medical needs using RNA-targeted technologies, today announced
that the Company’s President and Chief Executive Officer, Dr. Geert
Cauwenbergh, will present at the 15^th Annual BIO CEO & Investor Conference on
Monday, February 11^th at 4:00pm ET. Dr. Cauwenbergh will discuss the
development of RXI-109, a self-delivering RNAi compound designed to reduce
dermal scarring, as well as business development opportunities with RXi’s
sd-rxRNA® technology platform.

A live webcast of the presentation will be available on the “Investors”
section of the Company's website, www.rxipharma.com. A replay of the
presentation will be available 90 days.

Hosted by the Biotechnology Industry Organization (BIO), the 15^th Annual BIO
CEO & Investor Conference is the largest independent investor conference
focused on publicly-traded biotechnology companies. The conference will take
place February 11-12 at the Waldorf Astoria in New York City.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (OTC: RXII) is a biotechnology company focused
on discovering, developing and commercializing innovative therapies based on
its proprietary, self-delivering RNAi platform. Therapeutics that use RNA
interference, or “RNAi,” have great promise because of their ability to
down-regulate, the expression of a specific gene that may be over-expressed in
a disease condition. Building on the pioneering work of scientific founder and
Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board,
RXi’s first RNAi product candidate, RXI-109, which targets CTGF, entered into
human clinical development in June 2012. For more information, please visit
www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about future expectations, planned and
future development of RXi Pharmaceuticals Corporation’s products and
technologies. Forward-looking statements about expectations and development
plans of RXi’s products involve significant risks, and uncertainties: risks
that RXi may not be able to successfully develop its candidates, or that
development of RNAi-based therapeutics may be delayed or not proceed as
planned, or that we may not develop any RNAi-based product; risks that the
development process for our product candidates may be delayed, risks related
to development and commercialization of products by our competitors, risks
related to our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or organizations may
assert patent rights preventing us from developing our products. Actual
results may differ from those contemplated by these forward-looking
statements. RXi does not undertake to update forward-looking statements to
reflect a change in its views, events or circumstances that occur after the
date of this release.

Contact:

RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
 
Press spacebar to pause and continue. Press esc to stop.